Results for tag: "Secretase Inhibitor"

The Secretase Inhibitor market is a subset of the larger Alzheimer's Disease Drugs market. Secretase Inhibitors are a type of drug that target the enzymes responsible for the production of amyloid-beta, a protein that accumulates in the brains of Alzheimer's patients. These drugs are designed to reduce the amount of amyloid-beta in the brain, thus slowing the progression of the disease. Secretase Inhibitors are still in the early stages of development, and there are currently no approved drugs on the market. However, several pharmaceutical companies are actively researching and developing Secretase Inhibitors, and clinical trials are ongoing. Some of the companies in the Secretase Inhibitor market include Biogen, Eli Lilly, Merck, Novartis, and Pfizer. Show Less Read more